

Micaela M Hernberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2461239/publications.pdf>

Version: 2024-02-01

35
papers

5,872
citations

567281

15
h-index

395702

33
g-index

36
all docs

36
docs citations

36
times ranked

9485
citing authors

#	ARTICLE	IF	CITATIONS
1	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290.	3.7	4
2	Metastatic uveal melanoma: The final frontier. <i>Progress in Retinal and Eye Research</i> , 2022, 90, 101041.	15.5	36
3	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	1.9	4
4	Increased incidence of melanoma in children and adolescents in Finland in 1990â€“2014: nationwide re-evaluation of histopathological characteristics. <i>Annals of Medicine</i> , 2022, 54, 244-252.	3.8	4
5	Metastatic uveal melanoma managed with best supportive care. <i>Acta OncolÃ³gica</i> , 2021, 60, 135-139.	1.8	8
6	Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients. <i>Acta OncolÃ³gica</i> , 2021, 60, 803-807.	1.8	4
7	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. <i>Melanoma Research</i> , 2021, 31, 218-223.	1.2	4
8	Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma. <i>Melanoma Research</i> , 2021, 31, 224-231.	1.2	8
9	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 981-993.	3.4	22
10	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990â€“2014. <i>Acta OncolÃ³gica</i> , 2021, 60, 165-172.	1.8	3
11	Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients. <i>BJS Open</i> , 2021, 5, .	1.7	2
12	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
13	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. <i>Acta OncolÃ³gica</i> , 2020, 59, 310-314.	1.8	5
14	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119
15	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	4.2	18
16	Hepatic Ultrasonography Compared With Computed Tomography and Magnetic Resonance Imaging at Diagnosis of Metastatic Uveal Melanoma. <i>American Journal of Ophthalmology</i> , 2020, 216, 156-164.	3.3	8
17	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. <i>Acta OncolÃ³gica</i> , 2020, 59, 438-443.	1.8	7
18	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	1.4	45

#	ARTICLE	IF	CITATIONS
19	Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2019, 29, 561-568.	1.2	164
20	Cutaneous sarcoidosis after Hodgkin lymphoma. <i>International Journal of Dermatology</i> , 2019, 58, e17-e19.	1.0	0
21	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
22	Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. <i>Acta Oncologica</i> , 2018, 57, 1373-1380.	1.8	19
23	<i>BRAF</i> mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21566-e21566.	1.6	8
24	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2016, 128, 1099-1099.	1.4	7
25	Prospective immunohistochemical analysis of <i>BRAF</i> V600E mutation in melanoma. <i>Human Pathology</i> , 2015, 46, 169-175.	2.0	30
26	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
27	Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2014, 124, 799-799.	1.4	12
28	A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS9106-TPS9106.	1.6	4
29	Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma. <i>Medical Oncology</i> , 2011, 28, 1475-1480.	2.5	9
30	A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon- γ 2a as first line treatment in metastatic melanoma. <i>Melanoma Research</i> , 2010, 20, 318-325.	1.2	55
31	The Prognostic Role of Blood Lymphocyte Subset Distribution in Patients With Resected High-risk Primary or Regionally Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2007, 30, 773-779.	2.4	11
32	The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2004, 14, 493-500.	1.2	13
33	Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3770-3776.	1.6	69
34	Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 128-136.	0.8	39
35	Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 145-153.	1.1	22